Athira Pharma Inc., located in Bothwell, Washington, has agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act (FCA) by failing to report allegations of research misconduct to the National Institutes of Health (NIH) and Department of Health and Human Services (HHS) Office of Research Integrity in grant applications and grant award progress reports and assurances.
“The partnership between the scientific community and the federal government is built on trust and shared values of ethical scientific conduct,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “Today’s settlement demonstrates that the Justice Department will pursue grantees that undermine the integrity of federal funding decisions.”
“The research into neurological disorders such as Alzheimer’s and Parkinson’s Disease is critical to growing numbers of patients in our community,” said U.S. Attorney Tessa M. Gorman for the Western District of Washington. “That research must not be tainted by the misconduct highlighted in this case. To its credit, Athira immediately notified NIH of the research misconduct after the full board of directors learned of it. The company’s transparency significantly helped Athira mitigate its damages and demonstrated its resolve towards coming into compliance with the relevant law and regulations.”
“The failure of Athira to properly disclose allegations of falsified and manipulated scientific...
Channel 4’s newest true crime documentary Accused: The Fake Grooming Scandal focuses on the the case of Ellie Williams – the woman who lied about being raped, beaten, tortured and trafficked by a g...